

Curriculum Vitae

Janet Kinnear Kern, Ph.D.



Neuroscientist/ Researcher
Institute of Chronic Illnesses, Inc. /Dallas
408 N. Allen Dr.
Allen, Texas 75013
jkern@dfwair.net

Neuroscientist/ Researcher
Autism Treatment Center
10503 Metric Drive
Dallas, Texas 75243
972-644-2076
<http://www.atcoftexas.org/>
dr.kern@atcoftexas.org

Personal Statement

Dr. Kern is a neuroscientist and researcher who has conducted clinical research in children and adults with autism spectrum disorder (ASD) and other neurodevelopmental disorders for the last 20 years. She has over 60 peer-reviewed scientific research publications. The main focus of her research is in biomarkers of susceptibility, oxidative stress, neurodegeneration, neuroinflammation, toxicity, risk factors in ASD; brain changes related to mercury in neurodevelopmental disorders; and the role of dental amalgams in disease.

Her research also includes several treatment studies that examined the effectiveness of developmental interventions, medications, and nutraceuticals in ASD, such as DMG, secretin, Immunocal, equine-assisted activities, oral and transdermal glutathione, carnitine, and PlayWisely. She also has extensive experience in the medical field.

Editorial Boards

OA Autism, since 7/2013

Austin Journal of Autism & Related Disabilities, since 5/2014

Integrative Food, Nutrition and Metabolism (IFNM), since 8/2014

International Journal of Neurology Research, since 8/2014

Austin Journal of Neuropsychiatric & Clinical Neurosciences, since 8/2014

Journal of Biochemistry and Molecular Biology Research, since 10/2014

Affiliate Member

Publication Integrity & Ethics, since 11/2013

Reviewer for the following journals

OA Autism

Journal of Autism and Developmental Disorders

Journal of Child Psychology and Psychiatry

Journal of Toxicology and Environmental Health

Nutritional Research Reviews

Human & Experimental Toxicology

World Journal of Biological Psychiatry

International Journal of Biochemistry Research & Review

International Journal of Environmental Research and Public Health

Neurochemical Research

Neuroscience & Biobehavioral Reviews

Behavioral and Brain Functions

Mini Reviews in Medicinal Chemistry

Environmental Pollution

Ammons Scientific

Journal of Toxicology and Environmental Health Sciences

British Journal of Education, Society & Behavioural Science

PLOS One

Guest Editor Positions

BioMed Research International

The Biological Basis and Treatment of Autism and other Neurodevelopmental Disorders

Guest Editors: Janet K. Kern, Mark Geier, David Geier, Maria Dorota Majewska, Jose G. Dórea, Jyutika Mehta

Education

Ph.D. degree in Human Development and Communication Sciences/
Cognition and Neuroscience, August, 1999; GPA 4.0
University of Texas at Dallas, School of Human Development and
Communication Sciences, Richardson, Texas
Dissertation Topic: The Effectiveness of N, N-Dimethylglycine in Autism/PDD

M.S. degree in Cognition and Neuroscience, August, 1996; GPA 4.0
University of Texas at Dallas, School of Human Development and
Communication Sciences, Richardson, Texas

B.S. degree in Zoology/Physiology (Minor: Chemistry) June, 1987; GPA 3.8
University of Florida, Gainesville, Florida

A.S. degree in Nursing, May, 1980; GPA 3.4
Palm Beach Junior College, Lakeworth, Florida

Professional Experience

- 1/07 – present: Neuroscientist/ Research Director, Autism Treatment Center,
Dallas, Texas
- 12/08 – present: Neuroscientist/ Researcher, Institute of Chronic Illnesses –Dallas
Unit, Allen, Texas
- 1/06 – 9/14: Adjunct Assistant Professor, Department of Psychiatry, University
of Texas Southwestern Medical School, Dallas, Texas
- 11/02 –1/06: Assistant Professor, Department of Psychiatry, University of Texas
Southwestern Medical School, Dallas, Texas
- 9/02 – 7/09: Clinical Services Committee, Autism Treatment Center, Dallas and
San Antonio
- 7/00 – 10/02: Consultant for the Microdevelopmental Treatment in Autism study
at the University of Texas at Dallas, Texas
- 4/02 – 11/02: Senior Research Associate, Department of Psychiatry, University
of Texas Southwestern Medical Center, Dallas, Texas
- 10/99 – 4/02: Research Fellow in the Department of Psychiatry, University of
Texas Southwestern Medical Center, Dallas, Texas
- 9/97 – 9/99: Research/Teaching Assistant, School of Human Development,
University of Texas at Dallas, Richardson, Texas

- 5/96 – 10/97: Home Care Coordinator, Medical Center of McKinney, McKinney, Texas
- 5/89 – 5/95: Home Health Nurse, Visiting Nurse Association, McKinney, Texas
- 1/88 – 5/89: Home Health Nurse, Medical Center of McKinney, McKinney, Texas
- 5/83 – 12/86: Home Health Nurse, Upjohn Healthcare Services, Gainesville, Florida
- 6/80 – 4/83: Staff /Surgical Nurse, Alachua General Hospital, Gainesville, Florida

Awards and Honors

Minnie K. Patton Foundation Award for Academic Excellence, 1995.

Board Memberships

Advisory Board Member, OA Autism, Open Access Publishing London, since 3/2013

Council for Nutritional and Environmental Medicine (CONEM), Board Member since 3/2013.

Publications

Kern JK, Cauller LJ, Dodd M. Application of the Test of Nonverbal Intelligence (TONI-2) in children diagnosed with **autism**/PDD. *Journal of Developmental and Learning Disorders*, 2000;4(1):119-131.

Trivedi MH, **Kern JK**, Baker SM, Altshuler KZ. Computerized medication algorithms and decision support systems in major psychiatric disorders. *Journal of Psychiatric Practice*, 2000;6:237-246.

Kern JK. Good or bad research? How to tell the difference. **Autism** Asperger's Digest Magazine, September-October, 2000:14-19.

Kern JK, Miller VS, Cauller L, Kendall R, Mehta J, Dodd M. The effectiveness of N, N-Dimethylglycine in **autism**/PDD. *Journal of Child Neurology*, 2001;16(3):169-173.

Trivedi MH, **Kern JK**, Voegle T, Baker SM, Altshuler KZ. Computerized medical algorithms in behavioral health care. In: Dewan NA, Lorenzi N, Riley R, Bhattacharya

SR (Eds.) Behavioral Health Care Informatics. New York: Springer-Verlag, Inc., in cooperation with Springer-Verlag GmbH & Co., KG Berlin Heidelberg, 2001.

Kern JK, Miller VS, Evans PA, Trivedi MH. Efficacy of porcine secretin in children with **autism** and pervasive developmental disorders. *Journal of Autism and Developmental Disorders*, 2002;32(3):153-160.

Kern JK. The possible role of the cerebellum in **autism**/PDD; dysruption in a multisensory feedback loop. *Medical Hypotheses*, 2002;59(3):255-260.

Trivedi MH, **Kern JK**, Marcee AK, Kleiber B, Grannemann B, Bettinger T, Altshuler KZ, McClelland A. Development and implementation of computerized clinical guidelines: barriers and solutions. *Methods of Information in Medicine*, 2002;41:435-442.

DeBattista C, Trivedi MH, **Kern JK**, Lembke A. The status of evidence-based guidelines and algorithms in the treatment of depression. *Psychiatric Annals*, 2002;32(11):658-663.

Kern JK. Purkinje cell vulnerability and **autism**: a possible etiological connection. *Brain & Development*, 2003;25(6):377-382.

Kern JK, Waring RH, Ramsden DB, Grannemann BD, Garver CR, Trivedi MH. Abnormal sulfation chemistry in **autism**. In F. Columbus (Ed.), *Progress in Autism Research*. Hauppauge, NY: Nova Science Publishers, Inc.:2004.

Kern JK, Espinoza E., Trivedi, M. H. The effectiveness of secretin in the management of **autism**. *Expert Opinion on Pharmacotherapy*, 2004;5(20):379-387.

Kern JK, West EY, Grannemann BD, Greer TL, Snell LM, Cline LL, VanBeveren TT, Heartwell SF, Trivedi MH. Effects of psychosocial intervention on drug and alcohol involved mothers' parenting stress and depressive symptoms. *Maternal and Child Health Journal*, 2004;8(3):127-136.

Trivedi MH, **Kern JK**, Grannemann BD, Altshuler KZ, Sunderajan P. A computerized clinical decision support system as a means of implementing depression guidelines. *Psychiatric Services*, 2004;55(8):879-885.

Moller A, **Kern JK**, Grannemann BG. Are the non-classical auditory pathways involved in **autism** and PDD? *Neurological Research*, 2005;27:625-9.

Kern JK, Trivedi MH, Garver CR, Grannemann BD, Andrews AA, Savla JS, Johnson DG, Mehta JA, Schroeder JL. The pattern of sensory processing abnormalities in **autism**. *Autism*, 2006; 10(5): 480-494.

Kern JK, Jones AM. Evidence of toxicity, oxidative stress, and neuronal insult in **autism**. *Journal of Toxicology and Environmental Health, Part B.*, 2006;9(6):485-499.

Kern JK, Trivedi, MH, Grannemann BG, Garver CR, Johnson DG, Andrews AA, Savla JS, Mehta JA, Schroeder JL. Sensory correlations in **autism**. *Autism*, 2007; 11(2):127-138.

Kern JK, Garver CR, Grannemann BD, Trivedi MH, Carmody T, Andrew AA, Mehta JA. Response to vestibular sensory events in **autism**. *Research in Autism Spectrum Disorders*, 2007;1(1):67-74. <http://dx.doi.org/10.1016/j.rasd.2006.07.006>

Kern, JK, Bhaskara, L, Trivedi, MH. Evaluating secretin in the management of **autism**. *Journal Salud (i) Ciencia*. September 21st, 2006.
URL <http://www.siicsalud.com/dato/dat050/06920000.htm> .

Trivedi, M.H., Claassen, C.A., Grannemann, B.D., Kashner, T.M., Carmody, T.J., Daly, E., **Kern, J**. Assessing Physicians' Use of Treatment Algorithms: Project IMPACTS Study Design and Rationale. *Contemporary Clinical Trials*, 2007;28:192-212.

Kern JK, Grannemann BD, Trivedi MH, Adams J. Sulfhydryl-reactive metals in **autism**. *Journal of Toxicology and Environmental Health, Part A.*, 2007d;70(8):715-21.

Kern JK, Garver CR, Carmody T, Andrews AA, Trivedi MH, Mehta JA. Examining sensory quadrants in **autism**. *Research in Autism Spectrum Disorders*, 2007; 1:185-193.

Kern JK, Garver CR, Andrews AA, Carmody T, Mehta JA, Trivedi MH. Examining sensory modulation in individuals with **autism** as compared to community controls. *Research in Autism Spectrum Disorders*, 2008; 2(1): 85-94.

Kern JK, Grannemann BD, Gutman J, Trivedi MH. Oral tolerability of cysteine-rich whey protein isolate in **autism** – a pilot study. *JANA*, 2008;11(1):36-41.

Trivedi MH; Daly EJ; **Kern JK**, Grannemann BD, Sunderajan S, Claassen CA. Barriers to implementation of a computerized decision support system for depression: an observational report on lessons learned in "real world" clinical settings *BMC Medical Informatics and Decision Making* 2009, 9:6.

Geier DA, **Kern JK**, Garver CR, Adams JB, Audhya T, Geier MR. A prospective study of transsulfuration biomarkers in **autistic disorders**. *Neurochemical Research* 34(2):386-93, 2009.

Geier DA, **Kern JK**, Garver CR, Adams JB, Audhya T, Nataf R, Geier MR. Biomarkers of environmental toxicity and susceptibility in **autism**. Journal of Neurological Sciences. 280(1-2):101-8, 2009.

Geier DA, **Kern JK**, Adams JB, Garver CR, Geier MR. A prospective study of oxidative stress biomarkers in **autistic disorders**. Journal of Applied Psychology. 2009;5: 2-10.

Geier DA, **Kern JK**, Geier MR. A prospective study of prenatal mercury exposure from maternal dental amalgams and **autism** severity. Acta Neurobiol Exp. 69(2): 189-197.

Geier DA, **Kern JK**, Geier MR. A prospective blinded evaluation of urinary porphyrins versus the clinical severity of **autism spectrum disorders**. Journal Toxicology Environmental Health, Part A 2009;72:1585-1591.

Kern JK, Fletcher CL, Garver CR, Grannemann BD, Mehta JA, Knox KR, Richardson TA, Trivedi, MH. Prospective trial of equine-assisted activities in **autism spectrum disorders**. Alternative Therapies in Health and Medicine, 2011;17(3): 14-20.

Geier DA, Audhya T, **Kern JK**, Geier MR. Differences in blood mercury levels in **autism** spectrum disorders; is there a threshold level? Acta Neurobiol Exp. 2010;70:177-186.

Geier DA, **Kern JK**, Geier MR. Biological basis of **autism** spectrum disorders; understanding causation and treatment by clinical geneticists. Acta Neurobiol Exp. 2010;70:209-226.

Kern JK, Geier DA, Adams JB, Geier MR A Biomarker of mercury body-burden correlated with diagnostic domain specific clinical symptoms of **autistic disorders**. Biometals. 2010; 23 (6): 1043-1051.

Kern JK, Geier DA, Adams JB, Grannemann BD, Mehta JA, Geier MR. Toxicity biomarkers related to **autism** spectrum disorder: a blinded study of urinary porphyrins. Pediatrics International. 2011; 53(2):147-153.

Kern JK, Geier DA, Ayzac F, Adams JB, Garver CR, Mehta JA, Geier MR. Toxicity biomarkers among US children in comparison with French children: A prospective blinded study of urinary porphyrins. Toxicology & Environmental Chemistry, 93(2):396-405.

Geier DA, Carmody T, **Kern JK**, King P, Geier M. A significant relationship between mercury exposure from dental amalgams and urinary porphyrins: a further assessment of the Casa Pia Children's Dental Amalgam Trial. Biometals, 2011;24:215-24.

Kern JK, Geier DA, Adams JB, Troutman MR, Davis G, King PG, Young JL, Geier MR. **Autism** severity and muscle strength: a correlation analysis. *Research in Autism Spectrum Disorders*. 2011;5:1011-15.

Geier DA, **Kern JK**, Davis G, King PG, Adams JB, Young JL, Geier MR. A prospective double-blind, randomized clinical trial of levocarnitine to treat **autism spectrum disorders**. *Medical Science Monitor*. 2011;17:PI15-23.

Geier DA, Carmody T, **Kern JK**, King P, Geier M.A. Dose-dependent relationship between mercury exposure from dental amalgams and urinary mercury levels: a further assessment of the Casa Pia Children's Dental Amalgam Trial. *Human & Experimental Toxicology* 2012 31(1):11-17.

Kern JK, Geier DA, Garver CR, Adams JB, Audhya T, Nataf R, Geier MR. Efficacy of oral and transdermal glutathione in raising glutathione levels in **ASD**. *Medical Science Monitor*. 2011, 17(12):CR677-682.

David A, Geier DA, Clayman DA, Davis G., **Kern JK**, King PG, Pope J, Reents, L, Sykes LK, Young JL, Geier, MR. An evaluation of the role and treatment of elevated male hormones in **autism spectrum disorders**. *Acta Neurobiol Exp*, 2012;72(1):1-17.

Kern JK, Geier DA, Audhya T, King PG, Sykes L, Geier M. Evidence of parallels between mercury intoxication and the brain pathology in **autism**. *Acta Neurobiol Exp (Warsz)* 2012, 72: 113-153.

Rodriguez JI, **Kern JK**. Evidence of microglial activation in **autism** and its possible role in brain underconnectivity. *Neuron Glia Biology*, 2011; 7(2-4):205-13.

Geier DA, **Kern JK**, Geier, MR. Health, physical, and behavioral symptoms; a qualitative evaluation of **autism**. *Maedica (Buchar)*. 2012, 7(3):193-200.

Geier DA, **Kern JK**, King PG, Sykes LK, Geier MR. Hair toxic metal concentrations and **autism spectrum disorder** severity in young children. *Int J Environ Res Public Health*. 2012, 6;9(12):4486-97.

Kern JK, Geier DA, Sykes L, Geier M. Urinary porphyrins in **autism spectrum disorder**. In: *The Comprehensive Guide to Autism*. Eds: Patel VB, Preedy VR, Martin C. Springer, Science + Business Media. 2012. Chapter 72: <http://www.springerreference.com/docs/edit/chapterdbid/331181.html>.

Geier DA, **Kern JK**, King P, Sykes L, Geier M. Understanding the treatment of elevated male hormones in **autism**. In: *The Comprehensive Guide to Autism*. Eds: Patel VB, Preedy VR, Martin C. Springer, Science + Business Media. 2012. Chapter 71: <http://www.springerreference.com/docs/edit/chapterdbid/331180.html>.

Geier DA, **Kern JK**, King P, Sykes L, Geier M. Mercury induced **autism**. In: *The Comprehensive Guide to Autism*. Eds: Patel VB, Preedy VR, Martin C. Springer, Science

+ Business Media. 2012. Chapter 79:
<http://www.springerreference.com/docs/edit/chapterdbid/331188.html>.

Kern JK, Geier DA, Sykes LK, Geier MR, Deth RC. Are **ASD** and ADHD a continuum? A comparison of pathophysiological similarities between the disorders. *J Atten Disord.* (in press).

Kern JK, Geier DA, Adams JB, Troutman MR, Davis G, King PG, Young JL, Geier MR. Hand grip strength in **autism spectrum disorder** as compared to controls. *J Strength Cond Res.* 2013 27(8):2277-81.

Geier DA, **Kern JK**, Geier, MR. Comparison of the scores on the **Autism** Treatment Evaluation Checklist and the Childhood **Autism** Rating Scale. *Journal of Mental Health Research in Intellectual Disabilities.* 2013, 6:255-67.

Geier DA, Carmody T, **Kern JK**, King P, Geier M. A dose-dependent relationship between mercury exposure from dental amalgams and kidney integrity biomarkers: a further assessment of the Casa Pia Children's Dental Amalgam Trial. *Hum Exp Toxicol* 2013,32(4):434-40.

Kern JK, Garver CR, Mehta JA, Hannan PA, Bakken LE, Vidaud AM, Abraham J, Daoud Y. Prospective, blinded exploratory evaluation of the PlayWisely program in children with **autism spectrum disorder**. *Yale Journal of Biology & Medicine*, 2013, 13;86(2):157-67.

Kern JK, Haley BE, Geier DA, Sykes LK, King PG, Geier, MR. Thimerosal exposure and the role of sulfation chemistry and thiol availability in **autism**. *Int J Environ Res Public Health.* 2013,10(8):3771-800.

Kern JK, Geier DA, Sykes LK, Geier, MR. Evidence of neurodegeneration in **autism spectrum disorder**. *Translational Neurodegeneration.* 2013;2(1):17.

Kern JK, Geier DA, Geier, MR. Evaluation of regression in **autism spectrum disorder** based on parental reports. *NAJMS*, 2014, 6(1): 41-47.

Geier DA, Hooker BS, **Kern JK**, King PG, Sykes LK, Geier MR. A two-phase cohort study of the relationship between Thimerosal-containing vaccine administration as a risk factor for an **autism spectrum disorder** diagnosis in the United States. *Translational Neurodegeneration.* 2013 Dec 19;2(1):25.

Homme KG, **Kern JK**, Geier DA, Haley BE, King PG, Sykes LK, Geier, MR. New science challenges old notion that mercury dental amalgam is safe. *Biometals.* 2014 Feb;27(1):19-24.

Geier DA, **Kern JK**, King PG, Sykes LK, Homme KG, Geier MR. The risk of neurodevelopmental disorders following a Thimerosal-preserved DTaP formulation in

comparison to its Thimerosal-reduced formulation in the Vaccine Adverse Event Reporting System (VAERS). *Journal of Biochemical and Pharmacological Research* 2014, 2 (2): 64-73.

Hooker BS, **Kern JK**, Geier DA, Haley BE, Sykes LK, King PG, Geier MR. Methodological issues and evidence of malfeasance in research purporting to show Thimerosal in vaccines is safe. *Biomed Research International* 2014;2014:247218.

Kern JK, Geier DA, Sykes LK, Homme KG, Geier MR. Medical conditions in **autism** and events associated with the initial onset of autism. *OA Autism* 2014;2(1):9.

Geier DA, Hooker BS, **Kern JK**, King PG, Sykes LK, Homme KG, Geier MR. A dose-response relationship between organic mercury exposure from Thimerosal-containing vaccines and **neurodevelopmental disorders**. *IJERPH* 2014;11(9):9156-70.

Geier DA, **Kern JK**, Hooker BS, King PG, Sykes LK, Geier MR. Thimerosal-containing Hepatitis B vaccination and the risk for diagnosed specific delays in development in the United States: A case-control study in the Vaccine Safety Datalink. *NAJMS*, 2014; 6: 519-31.

Sykes LK, Geier DA, King PG, **Kern JK**, Haley BE, Chaigneau CG, Megson, Love J, Reeves RE, Geier MR. Thimerosal as discrimination: vaccine disparity in the UN Minamata Convention on mercury. *Indian Journal of Medical Ethics*, 11(4):206-18.

Presentations

Title: Neurobiology of Autism/PDD: Possible Role of the Cerebellum
Course: Cognitive Neuroscience/ Psychiatric Genetics, University of Texas Southwestern Medical Center, 1/2000.

Title: Neurobiology of Autism/PDD: Possible Role of the Cerebellum
Course: Advanced Clinical Neuroscience, University of Texas Southwestern Medical Center, 2/2000.

Title: Biology of Autism/PDD; Use of Secretin in Autism/PDD; Bowel Brain Connection in Autism/PDD
Course: Autism/Pervasive Developmental Disorders, University of Texas at Dallas – 7/2000.

Title: Efficacy of Porcine Secretin in Autism/PDD: A Case for Heterogeneity in this Disorder
Course: Cognitive Neuroscience/ Psychiatric Genetics, University of Texas Southwestern Medical Center, 9/2000.

Title: Neurobiology of Autism/PDD: Possible Role of the Cerebellum
Course: Advanced Clinical Neuroscience, University of Texas Southwestern Medical Center, 5/2001.

Title: Neurobiology of Autism/PDD: Possible Role of the Cerebellum
Course: Advanced Clinical Neuroscience, University of Texas Southwestern Medical Center, 9/2003.

Title: Sensory Processing in Autism
DANISH Group, Richardson, 8/2003

Title: Development of the Human Brain
STARS Program, University of Texas Southwestern Medical Center, 1/2004

Title: Sensory Processing in Autism: How Persons with Autism Differ from a Community Control Sample
North Texas Autism Summit – Dallas, 2004

Title: Development of the Human Brain
STARS Program, University of Texas Southwestern Medical Center, 1/2005

NBC Autism Special: Interviewed about metals research; aired 2/20/05.

Title: Development of the Nervous System
STARS Program, University of Texas Southwestern Medical Center, 3/2005

Title: Autism
STARS Program, University of Texas Southwestern Medical Center, 4/2005

Title: Toxic Metals and Autism
Psychology Synergy Conference, Collin County Community College, 10/2006

Title: Sulfhydryl-Reactive Metals in Autism
AWARES Online Autism Conference 10/2006

Title: Equine Assisted-Activities in Autism
NARHA/LSTEN Regional Conference , 8/2007

Title: Raising Glutathione Levels in Children with Autism
DAN! Think Tank, New Jersey, 4/2008

Title: A Prospective Study of Transsulfuration Biomarkers in Autistic Disorders and Biomarkers of Environmental Toxicity and Susceptibility in Autism USAAA Conference, Austin, Texas, September 7, 2008.

Title: Transsulfuration, Oxidative Stress, and Toxicity in Autism.

University of Texas Southwestern Medical Center, Dallas, Texas, January 15, 2009.

Title: Autism Urinary Porphyrin Results from Laboratoire de Biologie Medicale and LabCorp of America.

DAN! Think Tank, Dallas, Texas, January 17, 2009.

Title: Biomarkers of Susceptibility and Toxicity in Children with ASD.

ASA Conference in Dallas 7/9/2010.

Title: Susceptibility, Toxicity, and Brain Pathology in Autism Spectrum Disorder
Institut Pasteur, Paris, France, May 27, 2011

Title: Parallels between Mercury Intoxication and the Brain Pathology in Autism
BIOAUTISMO Seminario International, Santiago, Chile, March 19, 2012

Title: Overview of the Recent Research in Toxicity and Susceptibility, Brain
Inflammation and Connectivity, Regression and Immunizations in ASD.

AutismOne Conference, Chicago, Illinois, May 25, 2012.

Title: Mercury in Autism and Neurodevelopmental Disorders.

United Nations, Intergovernmental Negotiating Committee (INC-4) Meeting, Uruguay,
June, 2012.

Title: Mercury-Related Brain Changes Found in Neurodevelopmental Disorders.

IAMOT Conference, Austin, Texas, August, 2014.

Focus Group:

Department of Aging and Disability Services, Texas Autism Research & Resource Center
Website, Dallas Focus Group, July 19, 2010. Dallas, Texas.

Research Experience

Current Research:

No Identifying No. Kern (PI) 2013-2015

Evaluation of the Play Wisely Intervention in Autism II

Timberlawn Psychiatric Research Foundation.

Role: PI

No Identifying No. Kern (Co-PI) 2013-2015

Vaccine Safety Datalink

Institute of Chronic Illnesses, Inc.

Role: Co- PI

No Identifying No. Kern (Co-PI) 2011-2015
 Analysis of Florida Medicaid Database
 Institute of Chronic Illnesses, Inc.
 Role: Co- PI

No Identifying No. Kern (PI) 2011-2012
 Autism and Muscle Strength: Age, Race and Gender Matching Controls to ASD Data
 Already Collected - Addendum with Hormone Testing
 Autism Research Institute
 Role: PI

No Identifying No. Kern (PI) 2011-2015
 Stop Calling It Autism (SCIA) Immune Biomarkers in Autism
 SCIA.org
 Role: PI

No Identifying No. Kern (PI) 2011-2012
 Evaluation of the Play Wisely Intervention in Autism
 Timberlawn Psychiatric Research Foundation.
 Role: PI

No Identifying No. Kern (PI) 2011-2012
 Autism and Muscle Strength: Age, Race and Gender Matching Controls to ASD Data
 Already Collected
 Autism Research Institute
 Role: PI

No Identifying No. Kern (Co-PI) 2010-2011
 Further examination of the Casa Pia data
 The purpose of the study is to further examine the Casa Pia data
 International Academy of Oral Medicine and Toxicology (IAOMT), the non-profit
 Institute of Chronic Illnesses, Inc., and the non-profit CoMeD, Inc.
 Role: Co-PI

Completed Research:

No Identifying No. Kern (Co-PI) 2008-2010
 A double-blind, randomized clinical trial of L-carnitine to treat autism spectrum
 disorders.
 The purpose of the study is examine the efficacy of L carnitine in autism.
 Autism Research Institute
 Role: Co-PI

No Identifying No. Kern (Co-PI) 2008-2009
 Examining mercury blood levels in children with autism vs controls
 The purpose of the study is to compare blood Hg levels in autism vs controls.
 CoMed

Role: Co-PI

No Identifying No. Kern (PI) 2008-2009
Examining urinary porphyrins in French vs American children
The purpose of the study is to compare urinary porphyrins in French vs American children.
Autism Research Institute
Role: PI

No Identifying No. Kern (PI) 2007-2009
Examining urinary porphyrins in autism
The purpose of the study is to examine urinary porphyrins in autism.
Autism Research Institute
Role: PI

No Identifying No. Kern (PI) 2007-2008
Raising glutathione levels in Autism
The purpose of the study is to evaluate the use of oral and transdermal GSH supplementation in autism.
Autism Research Institute
Role: PI

No Identifying No. Kern (PI) 2006-2008
Evaluation of equine-assisted activities in persons with autism
The purpose of the study is to evaluate equine-assisted activities in children with autism.
Timberlawn Foundation
Role: PI

No Identifying No. Kern (PI) 2006-2007
Evaluation of whey protein as treatment in autism
The purpose of the study is to evaluate the use whey protein as treatment in autism.
Immunotec, Inc.
Role: PI

No Identifying No. Trivedi (PI) 2004-2006
IMPACTS
The purpose of this study is to examine the impact of implementation of evidenced-based algorithms via a computerized decision support system.
NIH
Role: Developer and liaison

No Identifying No. Trivedi (PI) 2004-2006
Aripiprazole Augmentation of SSRI Antidepressant
Therapy in Treatment Refractory Depression: Assessment of Symptom Reduction, Psychosocial Function, and Cognitive Function
Bristol Meyers Squibb

Role: Screening and cognitive testing

No Identifying No. Greer (PI) 2004-2006
Efficacy of Exercise Augmentation of SSRI Treatment in Improving Cognitive Function
in Major Depressive Disorder
National Alliance for Research on Schizophrenia and Depression/2004 Young
Investigator Award
Role: Screening and cognitive testing

No Identifying No. Trivedi (PI) 2004-2006
Assessment of Cognitive Function Before and After Treatment with Duloxetine
Eli Lilly Pharmaceuticals
Role: Screening and cognitive testing

No Identifying No. Kern (PI) 2004-2005
Heavy Metals and Head Circumference in Autism
The purpose of this study is to examine hair heavy metals in autism as compared to
gender-, age-, race-, and socioeconomic-matched controls, and then to examine the
relationship of the metals to head circumference.
Autism Research Institute
Role: PI.

No Identifying No. Trivedi (PI) 2002-2003
Technical Assistance for Algorithm Implementation
The purpose of this work is to implement CompTMAP into the Tarrant County MHMR
system
SAMSHA
Role: Project Director

No Identifying No. Trivedi (PI) 2003-2004
Technical Assistance for Algorithm Implementation
The purpose of this work is to implement CompTMAP into the Tarrant County MHMR
system
SAMSHA
Role: Project Director

No Identifying No. Trivedi (PI) 2001-2002
Computerized Platform for Medication Algorithms
The purpose of this work is to develop a computerized decision support system (CDSS)
for the treatment of major psychiatric disorders by psychiatrists and primary care
physicians.
Eli Lilly Pharmaceuticals
Role: RA

No Identifying No. Kern (PI) 2002-2004
Sensory dysfunction in autism

The purpose of this study is to examine sensory processing in autism/PDD.
Hogg Foundation
Role: PI.

No Identifying No. Moller (PI) 2004-2005
Involvement of non-classical auditory pathways in autism
The purpose of this study was to examine the processing of the classical and nonclassical auditory pathways and their possible role in hyperacusis in autism/PDD.
Role: Co-PI

No Identifying No. Kern (PI) 1999-2000
Efficacy of porcine secretin in children with autism/PDD
The purpose of this study was to examine the efficacy of porcine secretin in children with autism/PDD.
Role: PI

No Identifying No. Kern (PI) 1998-1999
The effectiveness of N, N-Dimethylglycine in autism/PDD
The purpose of this study was to examine the efficacy of DMG in children with autism/PDD.
FoodScience Corporation
Role: PI

No Identifying No. Kern (PI) 1997-1998
Application of the Test of Nonverbal Intelligence (TONI-2) in children with autism/PDD
The purpose of this study was to examine the use of a nonverbal test of cognition in children with autism/PDD.
Role: PI

Grant Awards

1998 - Award from FoodScience Corporation: \$2,387, plus DMG and placebo.
Research project: The effectiveness of N, N-Dimethylglycine in autism/PDD

2002 – Award from the Hogg Foundation for Mental Health: \$31,000.
Research project: Sensory dysfunction in autism

2004 – Award from the Autism Research Institute: \$20,000.
Research project: Heavy metals and head circumference in autism.

2006 – Award from the Timberlawn Foundation: \$39,981.
Research project: Evaluation of equine-assisted therapy in autism.

2006 – Award from Immunotec, Inc.: \$30,160.
Research project: Evaluation of whey protein as treatment in autism.

2006- Award from the Autism Research Institute, Inc.: \$40,000.
Research project: Raising glutathione levels in autism.

2007- Award from the Autism Research Institute, Inc.: \$30,000.
Research project: Raising glutathione levels in autism.

2008 – Award from the Autism Research Institute, Inc.: \$24,516.
Research project: Raising glutathione levels in autism.

2008 – Award from the Autism Research Institute, Inc.: \$15,000.
Research project: Measuring mercury-associated porphyrins in French vs US children.

2008 - Award from the Autism Research Institute, Inc.: \$49,000.
Research project: A double-blind, randomized clinical trial of L-carnitine to treat autism spectrum disorders.

2011 - Award from the Autism Research Institute, Inc.: \$4,920
Research project: Autism and muscle strength: age, race and gender matching controls to ASD data already collected.

2011- Award from the Timberlawn Psychiatric Research Foundation: \$27,190.
Research project: Evaluation of the Play Wisely Intervention in Autism

2011 - Award from the Autism Research Institute, Inc.: \$4,400
Research project: Autism and muscle strength: age, race and gender matching controls to ASD data already collected – addendum for hormone testing.

2013- Award from the Timberlawn Psychiatric Research Foundation: \$25,000.
Research project: Evaluation of the PlayWisely Intervention in Autism

Additional Training:

Imaging: fMRI, Talairach

Human Subjects: HIPAA, Human Subjects Training, Good Clinical Practices Biomedical Course in the Responsible Conduct of Research Curriculum completed 9/20/09 with Collaborative Institutional Training Initiative

Computer Training: Microsoft Word; Excel; Power Point; SAS; Neuron